Category Archives: Psoriasis

Psoriasis is a chronic skin disease which results in the person developing red, scaly patches all over their body. Some of the common areas of the body affected the most by the disease are scalp, knees and elbows.

It is a noncontagious disease that has become fairly common among people of all ages and is triggered by inflammatory chemicals produced by white blood cells called lymphocytes, Medicine Netreported.

Although its symptoms may range from small rashes to the entire body covered with thick, red plagues, depending on the level of the disease, it is the incurable nature of the disease that makes it one of the most intimidating skin diseases.

Read: Drug For Psoriasis Shows Results After 4 Weeks: Study

While it cannot be passed from one person to the next via direct contact or transfer of body fluids, it has been known to affect more than one member of the same family, indicating the hereditary nature of the disease, Web MD reported.

Many eminent personalities have previously opened up about suffering from the disease, eroding the social stigma attached to it.

Kim Kardashian

Kim Kardashian West attends the NBCUniversal 2017 Upfront in New York City, May 15, 2017. Photo: Getty Images/Angela Weiss

Reality star and fashionista Kim Kardashian has been perhaps the most vocal when it comes to addressing the struggles of psoriasis. She repeatedly spread awareness regarding the problem on her family reality show, Keeping Up With The Kardashians. However, Kardashian wasnt always as accepting of her chronic skin disease initially, according toHealthline.

She first realized she had psoriasis at the age of 30, incidentally the same age her motherKris Jenner discovered she suffered from the same skin disease. The socialite had almost given up on her career at that point.

Read:Biocon Launches Psoriasis Drug In India; To File IND Application With US FDA This Fiscal

"People don't understand the pressure on me to look perfect," she lamented on the show, Everyday Health reported. "When I gain a pound, it's in the headlines. Imagine what the tabloids would do to me if they saw all these spots?"

But all of that is in the past as the reality star, married to Kanye West, has now embraced her skin abnormality and is even seen advising step-sisterKylie Jenneron how best to tackle the problem as she too has inherited psoriasis.

Kardashian also posts pictures of her skin spots on Twitter.

Art Garfunkel

Grammy Award-winning American singer Art Garfunkel performs on stage at the Bloomfield Stadium in the Israeli city of Tel Aviv, Israel, June 10, 2015. Photo: Getty Images/Gil Cohen Magen

The singer who was one half of Simon & Garfunkel, bringing to the world 60s classics such as "Bridge Over Troubled Water" and "Sound of Silence,"Art Grfunkel also famously suffered from psoriasis and left no stones unturned when it came to treating the same. He had incorrectly learned water from the Dead Sea could help heal the disease. So he decided to try it out, but to no avail.

Ive been told that if you float in the salty, buoyant water, its very good for the skin. Its not so much therapeutic as beautiful, he wrote onhis website.

Britney Spears

Singer Britney Spears performs onstage at the iHeartRadio Music Festival at T-Mobile Arena in Las Vegas, Nevada, Sept. 24, 2016. Photo: Getty Images/Kevin Winter

Although the former teenage popstar secretly suffered from psoriasis for a long time, it was only in 2012 the skin condition of the Toxic singer hit the public eye.

Spears was booked as a judge on X Factor, a job which came with unprecedented stress, causing her skin to breakout in angry red rashes, which were clearly visible when she stepped out on the red carpet at the X Factor premiere party in Los Angeles.

"Britney has had the skin condition for a long time, but it only flares up when she's under extreme pressure, a source told National Enquirer, News reported. Now she can't seem to stop scratching and picking at the sores. She has a psoriasis skin cream, but she says it burns, so she stopped using it."

Dara Torres

Olympian Dara Torres waits for the start of the practice session for the 42nd Toyota Grand Prix of Long Beach Press Day in Long Beach, California, on April 5, 2016. Photo: Getty Images/Frederick M. Brown

Swimmer Dara Torres is one of the very few people who braved the chlorine-filled waters of the swimming pools while most others would remain wary of the same if they were diagnosed with psoriasis. The 12-time Olympic winner instead claimed the water actually soothedthe red spots on her skin, according to Health.

Torres has also been vocal against the stigma attached to the disease, saying athletes who suffer from psoriasis should not be self-conscious of their skin condition, especially when they are out in front of the world, competing to win.

"Psoriasis isn't contagious and it isn't just cosmetic," she says in a public service announcement. "It's a serious disease."

Jon Lovitz

Comedian/actor Jon Lovitz performs during the kickoff of his 20-show residency 'Reunited' with Dana Carvey at The Foundry at SLS Las Vegas in Las Vegas, Nevada, Jan. 6, 2017. Photo: Getty Images/Ethan Miller

Comedian Jon Lovitz is another celebrity who battled psoriasis for years now. The body of the Saturday Night Live and Rat Race star had 75 percentof his body covered in psoriasis spots at one point. However, he refused to give up and worked with a number of dermatologists to find a cure for his condition.

"Don't be embarrassed," he said in an interview with the National Psoriasis Foundation, according to the Health report. "See a dermatologist. A lot of people with psoriasis give up, but don't. Find out what works best for you.

LeAnn Rimes

LeAnn Rimes attends Luli Fama fashion show during Mercedes-Benz Fashion Week Swim 2015 at Cabana Grande at The Raleigh in Miami, Florida, July 20, 2014. Photo: Getty Images/Aaron Davidson

LeAnn Rimes, the country singer, was diagnosed with psoriasis at the age of two, and she proceeded to hide the condition from the world most of her life. At the age of six, 80 percent of her body was covered in red spots, and people around her started referring her as the scaly girl.

She would refrain from wearing short dresses which showed skin on red carpets. However, healthy lifestyle choices and medication prescribed by her dermatologist helped her recover from the problem.

By finally getting control over it instead of it having control over me, I wanted to speak out and let people know that there is hope, Rimes told Shape.

See the original post here:
What Is Psoriasis? Kim Kardashian, Britney Spears And Other Celebrities Suffering From The Skin Disease - International Business Times

GETTY

However, having a shower could be making them worse - if you live in a hard water area, that is.

This type of water is supplied to 60 per cent of UK homes, including the south east and east midlands.

However its been suggested that it aggravates skin conditions like eczema and psoriasis.

There are currently 1.7 million people in the UK with eczema, and cases have risen by 40 per cent in recent years.

GETTY

When the skin's barrier function is compromised, such as in eczema, the minerals can enter the skin as allergens causing inflammation and worsening eczema.

Dr Sharon Wong

Its a condition that causes the skin to become itchy, red, dry and cracked, according to the NHS.

Dr Sharon Wong, consultant dermatologist (www.drsharonwong.com), said: Hard water does not directly cause eczema but is a common aggravating factor in those who are genetically predisposed to developing eczema.

Hard water, which has a greater mineral content - mainly calcium and magnesium ions - has been linked to an increased risk of eczema and more severe disease in children.

When the skin's barrier function is compromised, such as in eczema, the minerals can enter the skin as allergens causing inflammation and worsening eczema.

Getty Images

1 of 11

Rosacea cures and treatments

GETTY

Similarly, psoriasis - which affects two to three per cent of the UK population - causes red, flaky, crusty patches of skin covered with silvery scales.

Whilst there is no evidence that hard water causes psoriasis, the fact that the minerals in hard water have a drying effect on the skin can worsen psoriasis and other dry skin problems, she explained.

Whether the water that comes out of your tap is soft or hard depends on the geology of your area, but there are ways to minimise or stop its negative effects on your skin.

Dr Wong added: This can be minimised by installing a water softener, using bath oils not bubble bath and using emollient/cream washes instead of soap.

GETTY

Both bubble bath and soaps contain surfactant which strips away the natural oils of your skin. Finally, using a regular and good moisturiser helps because it forms a protective layer on the skin thus preventing further fluid loss.

Sukhbinder Noorpuri, GP and CEO of i-GP, said: Hard water contains dissolved minerals such as calcium and magnesium. When used with soaps and detergents, this leaves a skin residue which blocks pores trapping oil, leading to irritation, dryness, blemishes and itching.

A water softener will reduce these skin issues, and convert the minerals found in hard water, into more soluble minerals that are less harmful for the skin.

Ecocamel have created the Shower Head ORB SPA which can convert hard water into soft water.

View original post here:
Eczema and psoriasis? THIS part of your morning routine could be triggering skin problems - Express.co.uk

Psoriasis increases the chances of myocardial infarction in younger psoriasis patients by three folds.

This press release was orginally distributed by SBWire

New York, NY -- (SBWIRE) -- 06/08/2017 -- Plaque psoriasis is a chronic, autoimmune inflammatory disorder which leads to overproduction of skin cells. The skin is characterized by inflamed, raised, scaly, red plaques and lesion. The intensity and frequency of psoriasis are affected by environmental factors such as sun exposure, smoking, HIV infection, and alcoholism. Metabolic syndrome and cardiovascular disease are common in psoriasis patients. Psoriasis increases the chances of myocardial infarction in younger psoriasis patients by three folds.

Moreover, severe psoriasis leads to 3.5 years reduced life expectancy in males relative to individuals without psoriasis. Psoriasis arthritis is a distinct syndrome which occurs in one-third of psoriasis patient with the onset of rheumatic arthritis.

Psoriasis plaque are distinguished by three features, an infiltrate featuring T-cells, the extravagant growth of poorly differentiated keratinocytes and the presence of dilated dermal blood vessels. Most of the introduced therapies for psoriatic were developed as to target T-cells or their inflammatory mediators including cytokines, receptors, and ligands.

Plaque Psoriasis Treatment Market: Dynamics

The demand for plaque psoriasis treatment market is expected to boom with the increasing number of pipeline psoriasis molecule and the number of biologics being launched. Janssen Biotec is seeking for the market approval of Guselkumab. The molecule is in the Phase III trial as a subcutaneous administered therapy for the treatment of plaque psoriasis.

Moreover, Gelantin Therapeutics Inc. announced positive data from its phase 2 study of its drug GR-MD-02 to treat moderate-to-severe plaque psoriasis. The company is now seeking for strategic partnership for its drug development program.

The advent of biologics has also shifted the preference from systemic therapy to meet the existing need. The systemic therapy suppresses the entire immune system as the clinician needs to do routine laboratory monitoring because of myelosuppression, hematologic side effects and increased renal and liver toxicity. Moreover, the systemic therapy is also contraindicated in nursing mothers, pregnant women, and individuals with kidney and liver diseases.

Around 125 million people worldwide have psoriasis out of which 80%, have plaque psoriasis. The need for safe plaque psoriasis therapy in children is essential as about one-third of the psoriasis cases are in children. Etanercept was approved by the DA as an extended indicated for children of age 4 and above.

Phototherapy and systemic therapy should only be used in cases where a topical treatment is inadequate. Novel systemic treatments are now being introduced where a range of biologics are sed. The mode of treatment follows a psoriasis treatment ladder. Initially, topical treatment is given, if the skin fails to respond then phototherapy is given. The third step involves the use of systemic treatment which may be through the administration of pills or injection.

TNF-? inhibitor was the first class of biologics which were successful in delivering the treatment while still maintaining the safety profile. Enbrel was the first molecule to be approved followed by Remicade and Humira. The introduction of these molecules increased the overall sales of the psoriasis drugs and also increased the physician's comfort and familiarity.

Plaque Psoriasis Treatment Market: Region-wise Outlook

North America region dominates the plaque psoriasis market owing to the increasing approval of pipeline drugs and supplemental biologics. In November 2016, the FDA approved supplemental biologics license for the use of Etanercept for children aged four and older having moderate-to-severe plaque psoriasis. The approval is the first of its kind indicated for the treatment of adults with moderate-to-severe plaque psoriasis. Amgen had performed a year-long phase 3 study and 5-year open-label extension testing for the approval.

A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/16069

AsiaPacific is expected to be the fastest-growing region owing to the huge population base and changing lifestyle habits such as smoking. Moreover, the global market players are also exploring the developing market. Novartis launched its Cosentyx in Japan for the treatment of psoriasis arthritis in adults who are not adequately responding to systemic therapy.

Plaque Psoriasis Treatment Market: Market Players

Company manufacturer is converting innovative research into a new therapy by constantly investing in research activities. The number of drugs approved for plaque psoriasis is constantly increasing the number of treatment options for the physician and patients. Eli Lilly's interleukin inhibitor was approved by the FDA, second molecule to be approved after Novartis Cosentyx.

Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/16069

Some of the plaque psoriasis treatment market contributors are Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

To Know About Latest Report Click Here: http://www.persistencemarketresearch.com/market-research/plaque-psoriasis-treatment-market.asp

For more information on this press release visit: http://www.sbwire.com/press-releases/plaque-psoriasis-treatment-market-estimated-to-flourish-by-2017-2025-persistence-market-research-817672.htm

Read more:
Plaque Psoriasis Treatment Market Estimated to Flourish by 2017 ... - Digital Journal

June 2, 2017

Psoriasis is an incurable chronic disease with a hereditary component, in which the body's immune system attacks parts of the skin. This leads to scaly red patches, which can be very itchy. About two million people in Germany have psoriasis, and 400 000 of them have a moderate to severe form of the disease.

Since 2015, the monoclonal antibody secukinumab (trade name: Cosentyx) has been approved for patients with moderate to severe plaque psoriasis. Since 2016, the monoclonal antibody ixekizumab (trade name: Taltz) has also been approved. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in two early benefit assessments whether these drugs offer an added benefit for patients in comparison with the appropriate comparator therapies. For both drugs, there are indications of considerable added benefit for certain patients.

Secukinumab: drug manufacturer submitted new dossier for one patient group

The older of the two drugs had already undergone an early benefit assessment in 2015. At that time, IQWiG had derived indications of a minor and of a non-quantifiable added benefit - but only for patients with no or inadequate response to previous systemic treatments or with contraindication or intolerance to such treatments. There are also those patients who are candidates for systemic treatment, but who have not yet received such treatment. The manufacturer applied for a new benefit assessment for this group because of new scientific findings.

No negative effects

For this new early benefit assessment, the manufacturer presented data from the study PRIME, in which fumaric acid esters were used in the comparator arm. In comparison with this comparator therapy, secukinumab showed very large positive effects in remissions, which resulted in an indication of an added benefit.

In addition, there was a hint of an added benefit in health-related quality of life and hints and indications of lesser harm in some side effects. There were no negative effects in any outcome. In summary, this resulted in an indication of considerable added benefit of secukinumab in patients who are candidates for systemic treatment.

Ixekizumab: only one of both studies usable

The other drug, ixekizumab, has been approved since 2016, but was not introduced into the market and subjected to an early benefit assessment before now because the manufacturer wanted to wait for new study results for this drug as well. The Federal Joint Committee (G-BA) again distinguished between two patient groups: patients who can receive systemic and/or phototherapy and patients with no or inadequate response to previous systemic treatments.

IQWiG could only analyse the data for the latter patient group because numerous participants who had already had phototherapy, i. e. a systemic treatment, had apparently been included in the study submitted by the manufacturer for patients eligible for systemic treatment. This specific research question of the benefit assessment can only be answered on the basis of patients who have not received previous systemic treatment, however.

Large positive effects also for this drug

For patients with no or inadequate response to previous systemic treatments, ixekizumab was compared with ustekinumab in the study IXORAS. The study is ongoing; data are available from an interim analysis after 24 weeks. Since there were notably more remissions under ixekizumab than in the comparator arm, there is an indication of a considerable added benefit in the outcome category "morbidity".

There is an indication of a minor added benefit for health-related quality of life. This is accompanied by an indication of greater harm in the outcome "general disorders and administration site conditions", which does not raise doubts about the positive effects, however. In the overall consideration, there is an indication of a considerable added benefit of ixekizumab in comparison with ustekinumab for adults with moderate to severe plaque psoriasis with no or inadequate response to previous systemic treatments.

Symptom analysis inadequate for course of the disease

"Both assessments show that there are notable advances for patients also outside oncology", says the Institute's Deputy Director Stefan Lange in view of the results. "This is good news. We have one suggestion for improvement, however: In both studies, disease-related symptoms were analysed only for fixed time points and only improvements were reported. This is inadequate for the typical course of the disease with its ups and downs. It would be better to present and analyse the burden of symptoms for each patient over the total study duration. There are simple methods for this purpose. This would also make temporary flare-ups and permanent improvements or deteriorations visible, which are generally of greater importance to the patients than their condition on a single fixed day."

G-BA decides on the extent of added benefit

The dossier assessments are part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessments, the G-BA conducts commenting procedures and makes final decisions on the extent of the added benefit.

Explore further: Secukinumab in plaque psoriasis: Manufacturer dossier provided no hint of an added benefit

More information: More English-language information will be available soon (extracts of the dossier assessments as well as easily understandable information on informedhealth.org). If you would like to be informed when these documents are available, please send an e-mail to info@iqwig.de.

Secukinumab (trade name: Cosentyx) has been approved since January 2015 for adults with moderate to severe plaque psoriasis. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment ...

Pembrolizumab (trade name: Keytruda) was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell ...

Secukinumab (trade name: Cosentyx) has been approved since November 2015 for adults with active ankylosing spondylitis or psoriatic arthritis. For patients with plaque psoriasis, the drug already underwent an early benefit ...

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. In a ...

The fixed-dose combination of the drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide has been available under the trade name Genvoya since November 2015 as treatment for adults and adolescents aged over ...

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy. In an early benefit assessment, the German Institute ...

In response to the rise in opioid overdose deaths nationwide, pharmaceutical companies have developed formulations of prescription opioids designed to prevent tampering or abuse. These "abuse-deterrent" forms, however, are ...

Almost one-third of new drugs approved by U.S. regulators over a decade ended up years later with warnings about unexpected, sometimes life-threatening side effects or complications, a new analysis found.

(HealthDay)EpiPensdevices used to rescue people during a severe allergic reactioncan remain effective years after their expiration date, a new study reports.

Top promoted drugs are less likely than top selling and top prescribed drugs to be effective, safe, affordable, novel, and represent a genuine advance in treating a disease, argue US researchers in The BMJ today.

A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found that physicians in academic medical centers (AMCs) prescribed fewer of the promoted drugs, and more non-promoted ...

A car crash shattered Stuart Anders' thigh, leaving pieces of bone sticking through his skin. Yet Anders begged emergency room doctors not to give him powerful opioid painkillershe'd been addicted once before and panicked ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original here:
Secukinumab and ixekizumab in psoriasis: Considerable added benefit for certain patients - Medical Xpress

Clinical Advisor

Coal tar: an anti-inflammatory treatment for psoriasis Clinical Advisor Coal tar products are most often used topically for a variety of skin conditions, including psoriasis. Coal tar is one of the oldest known treatments for psoriasis, as it reduces scaling, itching, and inflammation. Its exact working mechanism is not known.

Excerpt from:
Coal tar: an anti-inflammatory treatment for psoriasis - Clinical Advisor

RSOMtech uses lasers to generate ultrasound waves beneath the skin's surface (Credit: Helmholtz Zentrum Mnchen)

When doctors assess the inflammatory skin disease psoriasis, they generally do so via a visual examination of the red, scaly patches on the skin's surface. This can be subjective, however, plus it doesn't take into account what's going on at a deeper level. That's why German scientists from Helmholtz Zentrum Mnchen and the Technical University of Munich have developed a handheld scanner that looks beneath the skin and it doesn't expose the patient to any harmful radiation.

Known as RSOM (raster-scan optoacoustic mesoscopy), the technology incorporates weak laser pulses that are used to slightly heat the tissue being examined. This causes the tissue to momentarily expand, which in turn generates ultrasound waves. The sensor is able to detect those waves, and analyzes them to create a high-resolution image of what's happening under the skin.

NEW ATLAS NEEDS YOUR SUPPORT

Upgrade to a Plus subscription today, and read the site without ads.

It's just US$19 a year.

In lab tests performed on psoriasis patients, RSOM allowed the scientists to determine individuals' skin thickness, capillary density, number of blood vessels, and total blood volume in the skin. Down the road, it's possible that the system could also be used to assess diseases such as skin cancer or diabetes.

"This technology, which is easy to use and does not involve any radiation exposure or contrast agent, is allowing us to acquire the first new insights into the disease mechanisms," says Prof. Dr. Vasilis Ntziachristos, Director of the Institute of Biological and Medical Imaging at the Helmholtz Zentrum Mnchen, and Chair of Biological Imaging at the Technical University of Munich. "It also facilitates treatment decisions for the physicians."

A paper on the research was recently published in the journal Nature Biomedical Engineering.

Source: Helmholtz Zentrum Mnchen

Excerpt from:
Psoriasis sensor gets under peoples' skin - New Atlas - New Atlas

GETTY

A new drug for psoriatic arthritis has shown promise in a clinical trial.

The study by Stanford University found that it significantly reduced symptoms for sufferers.

These include joint tenderness and swelling.

Previously, standard pharmaceutical treatments had provided no effective or long-lasting relief.

GETTY

The findings are particularly important given that if left untreated, or treated unsuccessfully, the condition can develop into severe joint and bone damage and functional disability.

Researchers discovered that the biologic drug, ixekizumab, resulted in more than half of participants experiencing at least a 20 per cent reduction in the number of tender and swollen joints.

It also significantly out-performed the placebo.

In the study, the researchers looked at over 300 adults, for whom standard drugs were no longer working or never worked.

The findings are particularly important given that if left untreated, or treated unsuccessfully, the condition can develop into severe joint and bone damage and functional disability.

Getty

1 of 12

GETTY

About one in 200 adults in developed countries suffers from psoriatic arthritis.

The condition causes inflammation in and around the joints, according to Arthritis Research UK.

Symptoms usually appear between the ages of 30 and 50.

It usually affects those who already have psoriasis.

GETTY

The common skin condition causes red, scaly rash, especially on the elbows, knees, back, buttocks and scalp.

While the ultimate cause of the disease remains unknown, inflammation is the trigger.

A third of people will have a mild form of the disease that remains stable.

However others will have symptoms which need long-term treatment.

Link:
Arthritis news: Drug could treat condition linked to psoriasis - Express.co.uk

A new report has highlighted a severe lack of dermatology training and support within primary care. Dr Angelika Razzaque outlines the report's findings and what they mean for GPs.

A new report from the Patients Association, in partnership with LEO Pharma, has highlighted the severe lack of dermatology training1 and specialist support2 available for GPs.

Research shows that nearly a quarter of the population have sought GP advice on skin matters in England and Wales,2,3 yet some doctors have received just five days of dermatological training.1 There are only 650 dermatology consultants nationally to support them.2

The PSO What? initiative is a partnership programme led by The Patients Association and LEO Pharma, in collaboration with the expert PSO What? Taskforce. The PSO What? report highlights the need for better education and understanding surrounding the burden psoriasis places on individuals.

Psoriasis is one of several dermatological conditions where patient outcomes may be compromised by a lack of knowledge within primary care.

This condition affects over 1.8m people in the UK4 and it is essential to ensure tailored and holistic care to effectively manage the principal psoriasis symptoms, and also to reduce the risk of associated comorbidities.

The PSO What? Report takes a positive step forward in this direction. Developed in collaboration with an expert taskforce of healthcare professionals, patients and charities of which I am proud to be included - the report highlights that while GPs in the UK can handle around 13m appointments about skin conditions every year,2 no region in England has enough dermatology consultants when compared with recommendations from the Royal College of Physicians.2

Psoriasis needs higher prioritisation on health agendas, and stakeholders must respond by addressing the lack of practical dermatological training and formal assessment on educational curricula.

Beyond this, we as GPs should move away from the misconception that psoriasis is just a skin condition, and instead look for the best possible whole-person care for each individual.

A third of psoriasis patients surveyed as part of the PSO What? report do not regularly visit their GP each year.5 This is particularly concerning given people with psoriasis can also be at risk of developing other serious comorbidities6 including psoriatic arthritis,6 cardiovascular disease,7,8,9 metabolic syndrome,10 inflammatory bowel disease,6 complications with vision11 and some cancers.12

Aside from the physical aspects, the mental health of psoriasis patients should be taken into account. More than 10,000 diagnoses of depression and over 7,000 diagnoses of anxiety in the UK are attributable to psoriasis each year.13

General practice is a specialism of its own; our unique role in assessing the whole patient and addressing multiple comorbid conditions means that we are best placed to anticipate, prevent and manage associated conditions so that the broader burden of psoriasis can be reduced.

Given the right access to appropriate treatments and information, most people with psoriasis can be principally managed in partnership with GPs, nurses and pharmacists. By better educating GPs, we can ensure that appropriate patients are referred onto secondary care and primary care clinicians are confident in psoriasis diagnosis and treatment decision-making.

By reviewing our patients regularly, at least once a year, we have the opportunity to improve outcomes as well as helping to reduce life-limiting psoriasis complications and the potential burden on the NHS down the line.

The report calls for people from all walks of healthcare from universities, to GPs, consultants, payers and policymakers - to pledge their personal and professional support to drive real change by visiting http://www.PSO-What.com.

However, this will only prove effective if those in primary care are given the training and support required to confidently manage and treat the physical manifestations of psoriasis, as well as its associated complications and psychological effects.

To read the report and to pledge your support visit http://www.PSO-What.com.

Read this article:
Psoriasis: What can GPs do to deliver optimal care? - GP online

May 30, 2017 05:15 ET | Source: Research and Markets

Dublin, May 30, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Biosimilars Market Access in Psoriasis" report to their offering.

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent biosimilar launches.

Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. This rate of erosion may initially be gradual, as neither physicians nor payers are likely to advocate patient switching.

Key Topics Covered:

1. Executive Summary

2. Five Major EU Markets

3. Methodology

For more information about this report visit http://www.researchandmarkets.com/research/7tcv43/biosimilars

Related Articles

Research and Markets Logo

LOGO URL | Copy the link below

Formats available:

Go here to read the rest:
Biosimilars Market Access in Psoriasis 2017: TNF-alpha inhibitors Enbrel, Humira, and Remicade have Long Held ... - GlobeNewswire (press release)

the Irish News

Ask The Expert: How do I deal with my teenage son's psoriasis? the Irish News Q: "My teenage son has psoriasis and it's making his life a misery. What's the best way of dealing with it?" A: Consultant dermatologist Dr Anthony Bewley says: "Psoriasis isn't just a skin condition I see a lot of patients who struggle physically ...

Originally posted here:
Ask The Expert: How do I deal with my teenage son's psoriasis? - the Irish News